Supemtek Tetra (previously Supemtek) (quadrivalent influenza vaccine (recombinant, prepared in cell culture))
- Region
- 🇪🇺 EU
- Active substance
- quadrivalent influenza vaccine (recombinant, prepared in cell culture)
- Company
- Sanofi Winthrop Industrie
- Status
- Authorised
- Therapeutic area
- Influenza, Human
- CHMP opinion
- Thu 17 Sep 2020
- EU approval
- Mon 16 Nov 2020
- Application
- EMEA/H/C/005159
- ATC
- J07BB02
- Official record
- www.ema.europa.eu
Indication
Supemtek Tetra is indicated for active immunization for the prevention of influenza disease in adults and children from 9 years of age and older. Supemtek Tetra should be used in accordance with official recommendations.
Regulatory milestones
No milestones recorded in the last year.
Follow Supemtek Tetra (previously Supemtek)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.